Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I5WJ
|
|||
| Drug Name |
Blisibimod
|
|||
| Indication | Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 3 | [1] | |
| Company |
Anthera Pharmaceuticals Hayward, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell-activating factor (TNFSF13B) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NF-kappa B signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| Rheumatoid arthritis | ||||
| Reactome | TNFR2 non-canonical NF-kB pathway | |||
| TNFs bind their physiological receptors | ||||
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | ||||
| WikiPathways | Spinal Cord Injury | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.